Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01287325 | Efficacy of DNK333 in Patients With COPD and Cough | PHASE1 | COMPLETED | 28 | — | — | Sep 1, 2003 | - | Feb 1, 2011 | 2 | Netherlands, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| DNK333 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNK333 100 mg twice daily | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Mild to moderate COPD * Forced expiratory volume in 1 second (FEV1) ≥30% predicted * FEV1/FVC (forced vital capacity) \<70% * Significant amount of cough and minimal amount of sputum production, both as judged by self reporting Exclusion criteria: * Upper or lower airway inf...